仿制药市场规模预计将从2024年的4235.5亿美元增至2031年的5949.9亿美元。预计2024年至2031年期间,该市场的复合年增长率将达到5.0%。生物仿制药的日益普及可能会在未来几年为仿制药市场带来新的趋势。
仿制药市场分析
推动全球仿制药市场发展的因素包括政府对仿制药的政策和监管支持,以及专利到期和市场独占权的丧失。此外,政府为推广仿制药的使用而采取的举措日益增多,预计将为市场创造未来的增长机会。
仿制药市场概况
预计在预测期内,北美将主导仿制药市场,而亚太地区预计将实现显着增长,这得益于不断增长的医疗保健需求、注重成本的政府政策以及对可负担治疗方案的需求不断增加。中国和印度在制造业方面处于领先地位,日本和韩国专注于创新,而澳大利亚的生物技术投资不断增加,共同推动了市场扩张。同样,欧洲市场正在经历强劲增长。严格的欧盟法规、生物制剂采用率的提高以及制药制造业的不断增长推动了市场需求。德国在创新方面处于领先地位,英国和法国拥有强大的研发活动,意大利和西班牙正在扩大生产。由于医疗基础设施的改善、政府对仿制药的支持以及基本药物可及性的提高,南美洲和中美洲以及中东和非洲预计也将实现稳步增长,使其成为全球仿制药领域的新兴热点。
定制此报告以满足您的要求
您可以免费定制任何报告,包括本报告的部分内容、国家级分析、Excel 数据包,以及为初创企业和大学提供优惠和折扣
仿制药市场:战略洞察

- 获取此报告的顶级关键市场趋势。此免费样品将包括数据分析,从市场趋势到估计和预测。
仿制药市场驱动因素和机遇
专利到期和市场独占权丧失
据 Living Media India Limited 2025 报道,品牌药专利到期将显著推动仿制药市场的发展。专利到期后,仿制药制造商可以以低得多的价格生产和销售生物等效药物,从而创造巨大的市场机会。例如,在 2025-2026 年期间,Keytruda(由默克公司开发,用于癌症免疫治疗)和 Ozempic(由诺和诺德公司生产,用于治疗糖尿病和减肥症)等关键药物将失去专利。Keytruda 在 2024 年的销售额超过 250 亿美元。这一举措将为仿制药和生物类似药带来新的机会。其他高收入药物,如 Eliquis(百时美施贵宝的血液稀释剂)和 Cosentyx(诺华的免疫学药物),也将面临类似的专利到期,从而进一步扩大仿制药的机会。bioequivalent versions at significantly lower prices after the patent expiry, creating vast market opportunities. For instance, during 2025–2026, key drugs such as Keytruda (developed by Merck for cancer immunotherapy), which generated over US$ 25 billion in sales in 2024, and Ozempic (produced by Novo Nordisk for diabetes and anti-obesity treatment), are set to lose their patents. This initiative will develop new opportunities for generic pharmaceuticals and Eliquis (Bristol-Myers Squibb's blood thinner) and Cosentyx (Novartis' immunology drug), will face similar patent expirations, further expanding the opportunity for generics.
预计多种重磅药物的专利将于 2024 年到期,这将为仿制药创造更大的发展空间。值得关注的药物包括:
- Abilify Maintenancea(大冢制药)是一种注射用抗精神病药物,2022 年的销售额为 155 亿美元,预计将于 2024 年 10 月失去专利。
- 领先的抗凝剂 Xarelto(杨森制药)预计将于 2024 年 8 月失去其专利。
- Farxiga(阿斯利康)是一种重磅抗糖尿病药物,每年创造约 43 亿美元的收入,将于 2024 年失去其专利。
- 用于治疗癌症的 Lynparza(阿斯利康)销售额约为 27 亿美元,也将于 2024 年失去专利。
- 呼吸系统药物 Symbicort(阿斯利康)将于 2024 年 11 月失去专利。
- 诺华公司研发的心力衰竭治疗药物 Entresto 将于 2022 年创造 25 亿美元的收入,但该药物的专利将于 2024 年 5 月失效。
- Latuda(Sunovion Pharmaceuticals)是一种抗精神病药物,销售额达 18 亿美元,将于 2024 年 2 月失去专利。
- Xifaxan(Salix Pharmaceuticals)是一种胃肠药物,销售额达 16 亿美元,其专利将于 2024 年 6 月失效。
- 用于治疗晚期肾细胞癌的 Cabometyx(Exelixis)将于 2024 年 9 月失去专利。
这些药品共同创造了可观的全球收入,并为仿制药制造商开发更具成本效益的替代品创造了机会。2023年至2029年期间,包括抗癌、糖尿病和心血管药物在内的100多种关键药物的专利将到期,这些药物的全球年销售额将超过3000亿美元。专利权的丧失将显著扩大仿制药和生物类似药的市场份额,从而降低全球医疗保健成本。仿制药的涌入预计将重塑全球医药格局,提供更经济实惠的治疗选择。
预计这些动态将对印度产生显著影响。由于对平价药品的需求旺盛,仿制药已占据印度医药市场的很大份额。高收入药品专利到期预计将推动市场格局的转变,提高医疗保健的可负担性和可及性。据《印度快报》报道,2025年,这些重磅药物专利到期将推动仿制药和生物类似药的激增,为仿制药制造商提供巨大的增长机会。
政府加大推广仿制药的力度,为市场增长提供充足的机会
政府推广仿制药的举措为全球医药市场带来了重大机遇。许多政府,尤其是高收入国家的政府,越来越认识到仿制药的经济效益可以降低整体医疗支出。这些举措降低了政府和患者的用药成本,并促进了更多人获得基本治疗。例如,根据 GlobalData (2024) 的数据,一些国家为开具仿制药而非品牌药的医疗保健提供者提供经济激励。这些激励措施可能包括补贴、退税或根据开具仿制药的数量发放的奖金。此外,在美国等国家,医疗保险和医疗补助计划通常鼓励使用仿制药,从而提高了其在公共医疗体系中的应用率。
欧洲已出台监管措施,以确保仿制药更容易获得。例如,在德国和法国等国家,政府政策规定,除非开具处方的医生明确要求使用品牌药,否则药剂师在有仿制药的情况下必须提供仿制药。这种自动替代方法成功地提高了仿制药的采用率,并降低了患者和医疗系统的药品成本。在印度和巴西等新兴市场,政府也出台了推广仿制药的政策,以应对不断上涨的医疗成本。许多国家都制定了国家计划,以可负担的价格提供基本药物,通常依靠仿制药制造商来满足公共卫生需求。对仿制药使用的支持并不仅限于发达经济体。例如,根据人类数据科学研究所(2023)的数据,印度政府启动了“Jan Aushadhi计划”,该计划通过公共渠道以显著更低的价格提供仿制药。仅此一项计划就正在改变数百万人获得医疗保健的可及性。
随着政府对仿制药的支持力度加大,制药公司(尤其是仿制药生产企业)的机会也不断扩大。在医疗预算紧张、需要采取成本节约措施以确保民众能够获得药物的市场中,这一点尤为重要。
仿制药市场报告细分分析
有助于仿制药市场分析的关键部分是分子类型、适应症、类型和分销渠道。
- 根据分子类型,仿制药市场可细分为抗抑郁药、抗组胺药、镇痛药、抗生素、抗病毒药、利尿剂和其他药物。抗生素类药物在2024年占据了最大的市场份额,预计在2025年至2031年期间将实现最高的复合年增长率。
- 根据适应症,仿制药市场细分为代谢疾病、癌症、免疫学、呼吸系统疾病、心血管疾病、神经系统疾病、罕见疾病和其他疾病。癌症领域在2024年占据了最大的市场份额,而心血管疾病领域预计将在2025年至2031年期间实现最高的复合年增长率。
- 根据类型,仿制药市场分为处方药和非处方药。处方药在2024年占据市场主导地位,预计在2025年至2031年期间市场复合年增长率将更高。
- 从分销渠道来看,仿制药市场细分为医院药房、零售药房和在线药房。2024年,医院药房占据市场主导地位,预计在2025年至2031年期间,医院药房的复合年增长率最高。
仿制药市场份额地域分析
仿制药市场报告的地理范围主要分为五个地区:北美、亚太、欧洲、中东和非洲、南美和中美。
2024年,北美占据了相当大的市场份额,这得益于医疗成本上涨、人口增长、品牌药物专利到期激增以及对平价治疗方案的需求不断增长。美国、加拿大和墨西哥是主要贡献者,其中美国占据最大市场份额。到2030年,五分之一的美国人将超过65岁,这将增加对糖尿病、高血压和关节炎等慢性病的经济有效治疗的需求。政府支持和监管途径也增强了市场。美国食品药品监督管理局等机构加快了仿制药的审批途径,确保在不影响安全性和有效性的情况下更快地获得药物。这使得制造商更容易将仿制药推向市场。此外,对医疗成本控制的关注度日益增加。付款人和政策制定者提倡使用仿制药以降低总体支出。根据可及药物协会的数据,2023年仿制药占美国处方药的90%和药品支出的18%。市场竞争和整合也在加剧。市场参与者正在通过合作和收购来扩大投资组合,以扩大规模并满足不断增长的需求。
仿制药市场区域洞察
Insight Partners 的分析师已详尽阐述了预测期内影响仿制药市场的区域趋势和因素。本节还讨论了北美、欧洲、亚太地区、中东和非洲以及南美和中美洲的仿制药市场细分和地域分布。

- 获取仿制药市场的区域具体数据
仿制药市场报告范围
报告属性 | 细节 |
---|---|
2024年的市场规模 | 4235.5亿美元 |
2031年的市场规模 | 5949.9亿美元 |
全球复合年增长率(2024-2031) | 5.0% |
史料 | 2021-2023 |
预测期 | 2025-2031 |
涵盖的领域 | 按分子类型
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
仿制药市场参与者密度:了解其对商业动态的影响
仿制药市场正在快速增长,这得益于终端用户需求的不断增长,而这些需求的驱动因素包括消费者偏好的演变、技术进步以及对产品优势的认知度不断提高。随着需求的增长,企业正在扩大产品线,不断创新以满足消费者需求,并抓住新兴趋势,从而进一步推动市场增长。
市场参与者密度是指特定市场或行业内企业或公司的分布情况。它表明特定市场空间内竞争对手(市场参与者)的数量相对于其规模或总市值而言有多少。
在仿制药市场运营的主要公司有:
- 梯瓦制药工业有限公司
- Viatris公司
- 雷迪博士实验室有限公司
- 诺华公司
- 太阳制药工业有限公司
- 艾伯维公司
免责声明:以上列出的公司没有按照任何特定顺序排列。

- 获取仿制药市场顶级关键参与者概览
仿制药市场新闻和最新发展
仿制药市场评估是通过收集一手和二手研究的定性和定量数据进行的,这些数据包括重要的公司出版物、协会数据和数据库。以下列出了仿制药市场的一些发展情况:
- 2024年,艾伯维在欧盟推出PRODUODOPA(foslevodopa/foscarbidopa),用于治疗晚期帕金森病患者
- 2024 年,赛诺菲印度公司与 Emcure Pharmaceuticals 宣布建立独家心血管分销合作伙伴关系
仿制药市场报告覆盖范围和交付成果
《仿制药市场规模和预测(2021-2031)》报告对以下领域进行了详细的市场分析:
- 仿制药市场规模及全球、区域和国家层面所有主要市场领域的预测
- 仿制药市场趋势以及市场动态,例如驱动因素、限制因素和关键机遇
- 详细的 PEST 和 SWOT 分析
- 仿制药市场分析涵盖主要市场趋势、全球和、主要参与者、法规和最新市场发展
- 行业格局和竞争分析,涵盖市场集中度、知名参与者、仿制药市场的最新发展以及详细的公司简介
- 历史分析(2 年)、基准年、预测(7 年)及复合年增长率
- PEST 和 SWOT 分析
- 市场规模价值/数量 - 全球、区域、国家
- 行业和竞争格局
- Excel 数据集



Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
This text is related
to segments covered.

Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
This text is related
to country scope.
常见问题
The presence of government policies and regulatory support for generics and patent expiry and loss of market exclusivity are the most influential factors responsible for market growth.
The global Generic Drugs market is estimated to register a CAGR of 5.0% during the forecast period.
Thermo Teva Pharmaceutical Industries Ltd, Viatris Inc, Sun Pharmaceutical Industries Ltd, AbbVie Inc, Sanofi SA, and Glenmark Pharmaceuticals Ltd are among the key players operating in the Generic Drugs market.
North America dominated the Generic Drugs market in 2024.
The estimated value of the Generic Drugs market is estimated to reach US$ 594.99 billion by 2031.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies - Generic Drugs Market
- Teva Pharmaceutical Industries Ltd
- Viatris Inc
- Dr. Reddy's Laboratories Ltd
- Novartis AG
- Sun Pharmaceutical Industries Ltd
- AbbVie Inc
- AstraZeneca Plc
- Sanofi SA
- Aurobindo Pharma Ltd
- Glenmark Pharmaceuticals Ltd.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.